Philip Morris International (PM) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
21 Apr, 2026Executive summary
Achieved fifth consecutive year of volume growth, with net revenues surpassing $40 billion and smoke-free products contributing 41.5% of total net revenues for 2025, available in 106 markets and representing over 50% of net revenues in 27 markets and 3 of 4 regions.
Adjusted diluted EPS grew 14.8% year-over-year to $7.54, the strongest since 2011 (excluding 2021), with operating income margin above 40%.
Smoke-free shipment volumes rose 12.8%, with over 43 million adult consumers globally.
Consistent, best-in-class growth and commitment to rewarding shareholders, with confidence in outlook for 2026 and beyond.
Strong international performance, with ZYN shipments in the U.S. up 37% and robust growth in wellness and combustibles despite supply constraints.
Financial highlights
Full-year 2025 net revenues reached $40.6 billion, up 7.3% reported and 6.5% organically; Q4 organic net revenues grew 3.7% to $10.4 billion.
Gross profit was $27.3 billion, up 11.1% reported and 10.1% organically; operating income was $14.9 billion, up 11.1% reported and 10.6% organically.
Adjusted operating income margin for 2025 was 40.4%, up 1.6pp from 2024, with gross margin improved by 140 basis points.
Adjusted diluted EPS for 2025 was $7.54, up 14.8% year-over-year and 14.2% on a currency-neutral basis.
Operating cash flow for 2025 was $12.2 billion, matching the prior year.
Outlook and guidance
2026 organic net revenue growth forecast at 5%–7%, with organic operating income growth of 7%–9%.
2026 adjusted diluted EPS forecasted at $8.38–$8.53, representing 11.1%–13.1% growth over 2025, with currency-neutral growth of 7.5%–9.5%.
Operating cash flow for 2026 projected at approximately $13.5 billion, with net debt to adjusted EBITDA targeted near 2.0x by year-end.
2026–2028 guidance targets 6%–8% net revenue CAGR, 8%–10% operating income CAGR, and 9%–11% adjusted diluted EPS CAGR (currency-neutral).
Capital expenditures projected at $1.4–$1.6 billion in 2026.
Latest events from Philip Morris International
- Adjusted EPS up 16% to $1.96, with smoke-free products now 43% of revenue, led by IQOS.PM
Q1 202624 Apr 2026 - Proxy materials corrected to confirm Werner Geissler as Compensation Committee Chair.PM
Proxy filing31 Mar 2026 - Board recommends all director and management proposals, but opposes the ESG filter report.PM
Proxy filing26 Mar 2026 - 2026 proxy outlines virtual meeting, strong results, governance, and Board opposition to ESG proposal.PM
Proxy filing26 Mar 2026 - Smoke-free products drive growth, margin expansion, and strong shareholder returns for 2026–28.PM
Consumer Analyst Group of New York Conference (CAGNY) 202618 Feb 2026 - EPS growth of 13%-15% expected, fueled by smoke-free momentum and margin expansion.PM
Barclays 18th Annual Global Consumer Staples Conference 20253 Feb 2026 - Record H1 smoke-free growth drove raised 2024 guidance despite regulatory and currency headwinds.PM
Q2 20243 Feb 2026 - Smoke-free product growth and raised EPS guidance highlight a strong 2024 outlook.PM
21st Annual dbAccess Global Consumer Conference31 Jan 2026 - Strong NGP-driven growth, robust margins, and disciplined capital allocation define the outlook.PM
Barclays Global Consumer Staples Conference 202422 Jan 2026